Supplementary Table 1. Cell viability (%) of MDA-MB-231 and MDA-MB-468 after treatment with docetaxel and ABT-737 by MTT assay (Fig. 1B, C)
Concentration (μM) Docetaxel ABT-737
MDA-MB-231 MDA-MB-468 MDA-MB-231 MDA-MB-468
0 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0
0.001 100.3 ± 1.1 44.5 ± 1.8 104.5 ± 4.9 92.5 ± 12.7
0.01 78.5 ± 2.0 28.4 ± 5.4 105.4 ± 6.4 99.0 ± 11.7
0.1 58.8 ± 1.7 19.6 ± 1.8 103.3 ± 4.2 69.0 ± 1.7
1 58.1 ± 2.2 18.6 ± 3.0 84.2 ± 7.1 85.1 ± 9.7
2.5 61.5 ± 1.3 23.0 ± 5.7 54.1 ± 8.8 79.2 ± 13.6
5 64.7 ± 1.9 32.3 ± 3.0 29.9 ± 6.3 64.5 ± 7.8
10 68.4 ± 1.1 33.1 ± 4.1 10.1 ± 2.8 41.9 ± 7.0
20 71.3 ± 0.6 25.5 ± 7.6 0.5 ± 0.9 12.1 ± 3.7
40 72.9 ± 1.3 19.8 ± 5.8 1.1 ± 1.6 3.6 ± 1.9
Values are presented as mean ± standard deviation.
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
Supplementary Table 2. MTT absorbance at the wavelength of 570 nm after treatment with docetaxel, ABT-737, and combination using MDA-MB-231 (Fig. 2B)
Vehicle Docetaxel ABT-737 Combination
Absorbance (570 nm) 0.44 ± 0.03 0.43 ± 0.03 0.48 ± 0.07 0.28 ± 0.01
Values are presented as mean ± standard deviation.
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
Supplementary Table 3. Cell cycle analysis (% of each phase) after treatment with docetaxel, ABT-737, and combination using MDA-MB-231 cells (Fig. 3B, C)
Phase Vehicle Docetaxel ABT-737 Combination
SubG1 12.7 ± 2.7 26.0 ± 3.7 33.4 ± 5.2 59.6 ± 5.0
G1 48.0 ± 9.8 11.8 ± 0.9 4.0 ± 0.2 7.9 ± 0.8
S 18.3 ± 10.2 27.9 ± 2.9 38.8 ± 2.7 10.9 ± 1.1
G2/M 16.8 ± 0.7 16.1 ± 2.6 10.5 ± 2.7 9.1 ± 0.9
Values are presented as mean ± standard deviation.
Supplementary Table 4. Cell viability (%) after treatment with docetaxel, ABT-737, and combination using MDA-MB-231 with or without pretreatment of z-VAD-fmk by MTT assay (Fig. 4A)
Docetaxel ABT-737 Combination
z-VAD-fmk (-) 97.1 ± 6.4 107.9 ± 20.4 62.7 ± 1.7
z-VAD-fmk (+) 109.2 ± 11.6 119.2 ± 27.6 108.3 ± 18.9
Values are presented as mean ± standard deviation.
z-VAD-fmk, benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
Supplementary Table 5. Cell cycle analysis after treatment with docetaxel, ABT-737, and combination using MDA-MB-231 with or without pretreatment of z-VAD-fmk (Fig. 4C)
Phase Vehicle Docetaxel Docetaxel
+ z-VAD-fmk ABT-737 ABT-737
+ z-VAD-fmk Combination Combination + z-VAD-fmk
SubG1 14.8 24.2 19.5 25.4 1.4 40.8 9.6
G1 36.6 26.6 28.2 46.9 68.7 27.1 45.2
S 30.0 1.4 1.7 3.0 3.0 3.5 8.1
G2/M 17.1 9.4 14.5 9.1 16.5 10.0 18.3
Values are presented as mean ± standard deviation.
z-VAD-fmk, benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone.
